Deep sclerectomy with collagen implant: medium term results

Marc E Karlen, Enrique Sanchez, Corinne C Schnyder, Michel Sickenberg, André Mermoud

Abstract

Aims—To study prospectively the success rate and complications of deep sclerectomy with collagen implant (DSCI), a new non-penetrating filtration procedure.

Methods—Non-randomised prospective trial involving consecutive patients. 100 eyes of 100 patients with medically uncontrolled primary and secondary open angle glaucoma. A superficial scleral flap was raised and a deep sclerectomy was performed in the scleral bed. Schlemm’s channel was opened and dissection of the cornea was performed up to Descemet’s membrane, at which point aqueous percolated through the remaining trabecular-Descemet’s membrane. A collagen implant was sutured radially in the scleral bed. Visual acuity, intraocular pressure (IOP) measurements, and slit lamp examinations were performed before surgery and after surgery at 1 and 7 days, and 1, 3, 6, 9, 12, 18, 24, 30, and 36 months.

Results—The mean follow up period was 17.8 (SD 8.7) months. The mean preoperative IOP was 27.8 (8.6) mm Hg; the mean postoperative IOP was 5.7 (4.0) at day 1, 11.2 (4.6) at month 1, 14.0 (3.5) at month 12, and 13.0 (3.8) at month 36. Complete success rate, defined as an IOP lower than 21 mm Hg with medication, was 97.7% at 36 months. Qualified success rate, defined as an IOP lower than 21 mm Hg without medication, was 44.6% at 36 months.

Materials and methods

One hundred eyes of 100 patients with medically uncontrolled primary and secondary open angle glaucoma underwent DSCI. All study patients were enrolled consecutively. There were 58 male and 42 female patients, all white; mean age was 71 (SD 12.6) years (Table 1). The study was approved by the ethics committee of the University of Lausanne and informed consent was obtained from all participants. Inclusion criteria for the study were primary or secondary open angle glaucoma with uncontrolled intraocular pressure (IOP) while receiving maximal medical therapy, and willingness to be followed at the Jules Gonin Hospital. Uncontrolled glaucoma was defined as an uncontrolled IOP measured with a Goldmann applanation tonometer under maximal tolerable antiglaucomatous therapy with evidence of progression of the optic neuropathy and/or visual field defect. Exclusion criteria were angle closure glaucoma, unwillingness to participate in the study, known allergy to porcine derived products or collagen, previous eye surgery, previous argon laser trabecuoplasty less than 30 days before enrolment in the study, age less than 35 years, and presence of DSCI in the fellow eye.

Before surgery, all patients underwent best corrected visual acuity assessment (Snellen chart at 5 metres), biomicroscopy, gonioscopy, applanation tonometry with the Goldmann tonometer, visual field testing using the G1 program of the Octopus 101, and fundus examination. After surgery the same examinations, except for visual fields, were performed...
Deep sclerectomy with collagen implant

The aqueous humour flows out of the anterior chamber through the trabeculo-Descemet’s membrane, fills the scleral space (the pathway of which is maintained with the collagen implant), and then flows to the subconjunctival space.

Figure 1 (A) Schematic representation of the irido-corneal angle before deep sclerectomy with collagen implant. (B) Schematic representation of the irido-corneal angle after deep sclerectomy with collagen implant. The aqueous humour flows out of the anterior chamber through the trabeculo-Descemet’s membrane, fills the scleral space (the pathway of which is maintained with the collagen implant), and then flows to the subconjunctival space.

Table 1 Patient data (100 patients)

<table>
<thead>
<tr>
<th>Demographics:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years (SD))</td>
<td>71 (12.6)</td>
</tr>
<tr>
<td>Male/female</td>
<td>58/42</td>
</tr>
<tr>
<td>White/black</td>
<td>100/0</td>
</tr>
<tr>
<td>Preoperative IOP (mm Hg (SD))</td>
<td>27.8 (8.6)</td>
</tr>
<tr>
<td>Preoperative glaucoma medications (SD)</td>
<td>2.2 (0.8)</td>
</tr>
<tr>
<td>Follow up (months (SD))</td>
<td>17.8 (8.7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of glaucoma:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>POAG</td>
<td>52</td>
</tr>
<tr>
<td>PEXG</td>
<td>20</td>
</tr>
<tr>
<td>PSPHG</td>
<td>14</td>
</tr>
<tr>
<td>NPG</td>
<td>5</td>
</tr>
<tr>
<td>PIGG</td>
<td>3</td>
</tr>
<tr>
<td>OAGA</td>
<td>3</td>
</tr>
<tr>
<td>Other glaucoma</td>
<td>3</td>
</tr>
</tbody>
</table>

POAG = primary open angle glaucoma; PEXG = pseudoxfoliation glaucoma; PSPHG = open angle glaucoma in pseudophakic patients; NPG = normal pressure glaucoma; PIGG = pigmentary glaucoma; OAGA: open angle glaucoma in aphakic patients.

Surgical procedures

All surgeries were performed by one experienced surgeon (AM), using retrobulbar anaesthesia consisting of 2–4 ml of a solution of bupivacaine 0.75%, xylocaine 4%, and hyaluronidase 50 U.

Deep sclerectomy with collagen implant (Fig 1)

A superior rectus muscle suture was placed. The conjunctiva and Tenon’s capsule were then opened in the upper fornix and the sclera exposed; careful haemostasis using wet field cautery was performed. A one third scleral thickness limbus based scleral flap measuring 5 × 5 mm was dissected. This superficial scleral flap was dissected 1 mm into clear cornea. A triangle of deep sclera was then removed, leaving a thin layer of deep sclera over the choroid posteriorly. Anteriorly, the dissection was done down to the Schlemm’s canal, which was unroofed; more anteriorly, the excision of corneal stroma was done down to Descemet’s membrane. At this stage of the procedure, aqueous humour was seen to percolate through the remaining thin trabeculo-Descemet’s membrane. The cylindrical collagen implant drainage device measuring 1 × 1 × 2.5 mm was then placed radially in the centre of the deep sclerectomy dissection and secured with a single 10-0 nylon suture to the thin remnant, posterior to the Schlemm’s canal, scleral layer (Fig 2). The superficial scleral flap was repositioned over the collagen implant drainage device and secured with a single 10-0 nylon suture, and the knots buried. No tension was applied to these two sutures because there is no need for scleral flap resistance since the aqueous outflow resistance is located at the trabeculo-Descemet’s membrane. The conjunctiva and Tenon capsule were carefully closed with a running 9-0 Vicryl suture.

Postoperatively, patients were treated with topical dexamethasone 0.1%, neomycin 0.35%, and polymyxin 6000 U/ml (Maxitrol) three times a day for 2 weeks, and then with topical fluorometholone 1 mg three times a day for 3–6 months.

When a perforation of the thin trabeculo-Descemet’s membrane occurred during the corneal stroma dissection, the surgery was converted into a standard trabeculectomy, with a rectangular resection of the trabeculum, followed by a basal iridectomy.
Surgery was considered a complete success when IOP was < 21 mm Hg without glaucoma medication, a qualified success when IOP was < 21 mm Hg with glaucoma medication, and a failure when IOP was > 21 mm Hg with or without glaucoma medication, or when an eye required further glaucoma drainage surgery, developed phthisis bulbi, or lost light perception. Three measurements of the IOP were performed to determine the mean IOP; when this mean IOP was > 21 mm Hg, it was considered as failure.

When the filtering bleb at any postoperative visit was encysted or showed signs of fibrosis, subconjunctival injections of 5 mg of 5-fluorouracil (5-FU) were performed in the lower quadrant, opposite the deep sclerectomy with collagen implant. The subconjunctival injections consisted on 0.1 ml of a 50 mg/ml solution of 5-FU (250 mg/5 ml fluorouracil, Roche (Basle, Switzerland). Subconjunctival 5-FU injections were repeated up to seven times if needed.

Goniopuncture with the Nd:YAG laser (Microruptor II, Lasag AG, Thun, Switzerland) was performed when the filtration through the trabeculo-Descemet's membrane was suspected to be insufficient, either because of a shallow filtration bleb or elevated IOP. The laser treatment was performed using a Lasag-15 gonioscopy contact lens (CGA1). Goniopuncture was performed using the free running Q switch mode with energy ranging from 2 to 4 mJ. The goal of the laser treatment was to create a small hole in the trabeculo-Descemet's membrane, which is technically similar to posterior capsulotomy after cataract surgery. Goniopuncture allows direct passage of aqueous from the anterior chamber to the filtration bleb and transforms the non-perforating filtering surgery into a perforating filtering surgery. After laser treatment, patients were treated with topical prednisolone acetate (Predforte) three times a day for 3 days. Laser goniopuncture was considered a success when final IOP was < 18 mm Hg, or when the decrease in IOP was > 5 mm Hg with initial pressure < 23 mm Hg.

GONIOPLASTY WITH A CYLINDRICAL COLLAGEN IMPLANT
The cylindrical collagen implant is manufactured by Staar Surgical AG, Nidau, Switzerland. It measures 2.5 mm in length and 1 mm in diameter. The collagen implant is processed from lyophilised American porcine scleral collagen, which is sterilised by a radiation procedure. Microbiological analyses performed...
by Professor Nordmann, Hôpital Antoine Beclere in Paris on 30 g of raw collagen material have not revealed the presence of bacteria, virus, mycological organisms, and parasites. The water content of the hydrated device is 99% (Fig 3). The collagen device is resorbed within 6–9 months after surgery as was documented in a previous ultrasonographic study.10 11

STATISTICAL ANALYSIS
Results were analysed using the Student’s t test for comparison of means, χ² analysis for 2 × 2 tables, and Kaplan–Meier survival curves for long term success rate analysis; for comparison between groups, the Wilcoxon test was used.

Results
Of 106 patients on whom DSCI was planned, six were found to have a perforation of the thin trabeculo-Descemet’s membrane at the time of surgery, so the procedure had to be converted into a trabeculectomy. These six patients were excluded from the study. In the first 10 deep sclerectomies, iatrogenic perforation of the trabeculo-Descemet’s membrane during surgery occurred three times (30%), whereas in the subsequent 96 surgeries the membrane was perforated only three times (3.1%).

The mean follow up time was 17.8 (SD 8.7) months. The IOP at 3 months was reduced by 55.4% (12.4 (3.9) versus 27.8 (8.6) mm Hg), and at 36 months was reduced by 53.2% (13.0 (3.8) versus 27.8 (8.6) mm Hg), thus showing stability of the IOP postoperatively (Fig 4).

Eyes treated with DSCI had a complete success rate at 36 months of 44.6%; the qualified success rate was 97.7% at 36 months (Fig 5). The mean number of medications per patient required to control IOP was reduced from 2.2 (0.7) before DSCI to 0.2 (0.4) after DSCI, (p = 0.001 ). On the first postoperative day, best corrected visual acuity (UK notation) was 6/12 (6/18). Visual acuity returned to preoperative levels 1 week after surgery and remained stable for the following 3 years (Fig 6). Postoperative complications that occurred are listed (Fig 7). We observed no shallow or flat anterior chamber, no anterior chamber inflammation, no bleb related endophthalmitis, and no surgery induced cataract. However, 7% of patients showed a progression of pre-existing cataract. Bleb fibrosis and encapsulation were treated with 5-FU subconjunctival injections. Subconjunctival injections of 5-FU were made in 23 patients who underwent DSCI. The mean number of injections per patient was 2.9 (2.2) and the mean time between operation and 5-FU injection was 1.9 (2.7) months.

Goniopuncture with the Nd:YAG laser was performed in 41 patients at various times after DSCI. The mean time between surgery and goniopuncture was 11.0 (7.5) months. Mean IOP before goniopuncture was 22.2 (7.0) mm Hg and decreased to 12.3 (5.8) mm Hg, the success rate being 83%.

Comparing the result of the three main glaucoma categories (primary open angle glaucoma (52 patients), pseudoexfoliative glaucoma (20 patients), and open angle glaucoma in pseudophakic patients (14 patients), it was found that patients with primary open angle glaucoma were younger, 68.9 (12.1) versus 75.7 (7.8) and 76.4 (10.5), for pseudoexfoliative glaucoma and open angle glaucoma in pseudophakia, respectively. There was no significant difference in terms of postoperative IOP, qualified success rate, or number of postoperative glaucoma medications. However, there is a tendency of lower medium term success rate in the PSPHG group (Table 2).

Discussion
In an attempt to avoid the numerous postoperative complications of trabeculectomy, such as hypotony, flat anterior chamber, and choroidal detachment, some authors proposed a tight closure of the scleral flap with secondary suture lysis with the argon laser.12 More recently, for the same reason, several techniques of non-perforating filtration surgery have been described. Zimmerman et al13 14 reported good results of non-penetrating trabeculectomy in phakic and aphakic patients. Arenas15 developed a technique called ab externo trabeculectomy, and reported a success rate of 88%.  

Figure 6  Evolution of the mean visual acuity after DSCI.

Figure 7  Postoperative complications.

A, bleb encapsulation
B, choroidal detachment
C, wound leak
D, bleb fibrosis
E, hyphaema
F, cataract progression
G, corneal abscess
H, malignant glaucoma
I, dellen
J, hypotony

Deep sclerectomy with collagen implant

Figure 6 Evolution of the mean visual acuity after DSCI.
Other authors who used the ab externo technique reported control of IOP in 85.8% to 90% of patients. Stegmann described a similar technique, in which the scleral space was filled with a viscoelastic substance, and reported complete success in 61% of patients and qualified success in 77% at 26 months of follow up.

To enhance the filtration of deep sclerectomy, Kozlov et al. and Fyodorov described the use of a collagen implant placed within the scleral bed. Similarly, in a prospective and randomised study, we achieved better surgical outcome when the collagen implant was used.

The major advantage of DSCI is that it precludes the sudden hypotony which occurs following trabeculectomy by creating progressive filtration of aqueous humour from the anterior chamber to the subconjunctival space, without perforation of the eye. In an experimental model, Mermod and Vaudaux studied the aqueous dynamics through the remaining thin trabeculo-Descemet’s membrane, and found that the outflow resistance was low but sufficient to avoid the immediate postoperative complications often seen after trabeculectomy.

The short term success of DSCI has been reported to be good. Demailly et al. reported a mean decrease in IOP of 9.1 (7.1) mm Hg after 219 DSCI procedures. Using Kaplan–Meier survival analysis, they reported a success rate without glaucoma medication of 89% at 6 months, and 75.6% at 16 months; with glaucoma medication, their success rate increased to 97% at 6 months, and 79% at 16 months. Kozlov et al. reported an 85% success rate, but no information regarding success criteria or follow up is available. The mid-term (36 months) success of DSCI remains satisfactory. The complete success rate of DSCI was 97% at 6 months, 71.4% at 24 months, and 44.6% at 36 months. With glaucoma medication, the success rate was 90% at 6 months, and 97.7% at 36 months. Interestingly, in our study, although the preoperative age and IOP was different in the three main glaucoma groups (Table 2), the postoperative success rates were similar. This may be explained by the reproducibility of the trabeculo-Descemet’s membrane resistance which allows similar postoperative IOP regardless of preoperative levels. For other types of glaucoma such as pigmentary glaucoma, aphakic glaucoma, traumatic glaucoma, and other more rare secondary open angle glaucomas, no difference could be found in terms of postoperative results, but the number of cases was too small for statistical analysis.

Table 2  Comparison of results of deep sclerectomy with collagen implant between primary open angle glaucoma (POAG), pseudoexfoliative glaucoma (PEXG), and open angle glaucoma in pseudophakic patients (PSPHG).

<table>
<thead>
<tr>
<th></th>
<th>POAG</th>
<th>PEXG</th>
<th>PSPHG</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (SD)</td>
<td>68.9 (12.1)</td>
<td>75.7 (7.8)</td>
<td>76.4 (10.5)</td>
<td>&lt; 0.03*</td>
</tr>
<tr>
<td>Preoperative IOP (mm Hg) (SD)</td>
<td>26.3 (7.7)</td>
<td>30.5 (8.1)</td>
<td>28.9 (10.0)</td>
<td>0.058</td>
</tr>
<tr>
<td>Postoperative IOP (mm Hg) (SD)</td>
<td>14.3 (3.2)</td>
<td>13.2 (3.5)</td>
<td>12.5 (3.4)</td>
<td>NS</td>
</tr>
<tr>
<td>12 months</td>
<td>12.9 (3.3)</td>
<td>13.3 (3.5)</td>
<td>13.4 (4.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Complete success rate (%) 30 months</td>
<td>75.8</td>
<td>71</td>
<td>57</td>
<td>NS</td>
</tr>
<tr>
<td>Qualified success rate (%) 30 months</td>
<td>98</td>
<td>100</td>
<td>100</td>
<td>NS</td>
</tr>
<tr>
<td>Number of preoperative glaucoma medications (SE)</td>
<td>2.1 (0.6)</td>
<td>2.4 (0.8)</td>
<td>2.4 (0.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of postoperative glaucoma medications (SE)</td>
<td>0.2 (0.3)</td>
<td>0.2 (0.4)</td>
<td>0.3 (0.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients having 5-FU injections</td>
<td>11/52 (21%)</td>
<td>4/20 (20%)</td>
<td>3/14 (21%)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients having gonioscopic entry</td>
<td>18/52 (21%)</td>
<td>10/20 (50%)</td>
<td>6/64 (43%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

POAG patients are significantly younger than those with PEXG or PSPHG.

* POAG patients are significantly younger than those with PEXG or PSPHG.

NS = not significant; IOP = intraocular pressure; SE = standard error; SD = standard deviation; 5-FU = 5-fluorouracil.
chamber remained deep and the IOP controlled. The scopolamine was then discontinued and the patient developed malignant glaucoma with shallow anterior chamber, rotation of the ciliary body assessed by ultrasound biomicroscopy, and elevated IOP. The patient was successfully treated with scopolamine for another 2 months.

Although DSCI is a safe procedure with few immediate postoperative complications, careful long term follow up is necessary. In our series, 34 patients developed fibrosis or an encysted bleb. These patients were treated with subconjunctival injections of 5-FU. The mean number of injections required per patient (2.9 (SD 2.1)) was much lower than in previous studies using 5-FU after trabeculectomies (7–21 injections).

The majority of 5-FU injections were made during the first 2 postoperative months.

Goniopunctures with the Nd:YAG laser were performed in 41% of the patients. Goniopuncture was performed shortly after DSCI because there was insufficient percolation of aqueous humour at the trabeculo-Descentem’s membrane, probably due to the lack of surgical dissection. When goniopunctures were required at a later time (more than 9 months after initial surgery), low filtration was probably the result of fibrosis of the trabeculo-Descentem’s membrane, since goniopuncture resulted in increased filtration of aqueous humour and decreased IOP. The success rate of Nd:YAG laser goniopuncture was satisfactory, with an IOP decrease of 43.7% (from 22.2 (7.0) to 12.5 (5.8) mm Hg). By opening the trabeculo-Descentem’s membrane, however, goniopuncture transformed a non-perforating filtration procedure into a perforating one. Because this perforation can lead to the classic complications (flat anterior chamber and choroidal detachment) of trabeculectomy when performed early after DSCI, we usually wait 3 weeks or more before performing goniopuncture. Although the potential risk of late bleb related endophthalmitis may be increased after goniopuncture, no such case occurred in our study.

Kozlov et al. also reported early and late postoperative ocular hypertension, and also performed goniopunctures with the Nd:YAG laser, and they achieved a success rate ranging from 85 to 94%. Demailly et al. in their series of 219 DSCI procedures, performed 90 gonipunctures with the Nd:YAG laser, of which 61 (68%) were successful. These results compare favourably with our success rate of 85%.

Several questions about DSCI remain unanswered: What is the mechanism of aqueous percolation through the thin trabeculo-Descentem’s membrane? What tissue replaces the thin scleral layer that is left in the deep scleral bed? Does aqueous drain into Schlemm’s canal and the aqueous vein? To answer these questions, further studies are needed. Furthermore, long term (5–10 years) clinical follow up studies are necessary.

In conclusion, DSCI appears to be a promising new non-perforating filtration procedure. In our hands, the success rate after 3 years of follow up was satisfactory for all types of primary and secondary open angle glaucoma studied. The immediate postoperative complication rate was low, and visual acuity was almost unaffected. Preservation of the thin trabeculo-Descentem’s membrane, however, is technically challenging, particularly before the surgeon gains experience with this procedure. In addition, careful postoperative examinations are needed to identify and treat early and late postoperative ocular hypertension with the Nd:YAG laser, as well as to identify and treat bleb fibrosis and encysted blebs with subconjunctival injections of 5-FU.


Dr Mermoud is a consultant for Staar Surgical AG, Nidau, Switzerland.

Deep sclerectomy with collagen implant: medium term results

Marc E Karlen, Enrique Sanchez, Corinne C Schnyder, Michel Sickenberg and André Mermoud

Br J Ophthalmol 1999 83: 6-11
doi: 10.1136/bjo.83.1.6

Updated information and services can be found at:
http://bjo.bmj.com/content/83/1/6

These include:

References
This article cites 17 articles, 1 of which you can access for free at:
http://bjo.bmj.com/content/83/1/6#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Angle (1006)
Glaucoma (988)
Intraocular pressure (1002)
Ophthalmologic surgical procedures (1223)
Anterior chamber (26)
Lens and zonules (807)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/